

No Difference in Local Recurrence Rates for Surgical vs. Non-surgical Treatment of Penile Squamous Cell Carcinoma In Situ



Background

- Patients with penile symptoms often delay seeking care due to a myriad of reasons including embarrassment, guilt, and fear^{1,2}
- Historically, genital dermatologic lesions are an area of particular diagnostic difficulty with additional challenges in management³
- Penile Squamous Cell Carcinoma in situ (PSCCis) management has only been assessed in small series
- NCCN guidelines recommend topical therapy, wide local excision, laser therapy, glansectomy, or Mohs Micrographic surgery (MMS) as treatment
- There is no consensus on which therapy is preferred
- Currently, excision and topical therapy are most commonly used

Objective

• To evaluate treatment outcomes of PSCCis and compare surgical versus non-surgical management

Methods

- All records between 1/1/96 and 10/31/20 at BWH, MGH, and MSKCC Hospital were searched for patients with a confirmed histologic diagnosis of malignant neoplasm of the penis
- Tumors with insufficient primary tumor information or a diagnosis other than cutaneous squamous cell carcinoma in situ or high-grade penile intraepithelial neoplasia (PelN III) were excluded, duplicate records were also excluded
- Medical records were examined for patient characteristics, tumor characteristics, and outcomes of interest including local recurrence, nodal metastasis, distant metastasis, and disease-specific death

Patie

All pa Race, Wł No HPV No

Docu No Yes Ur Circu No

Yes Un Docu No

Docu Nc Yes

Tum All Pr

Age a Overa Tumo Tumo Glan Fore

Shaf Over **Multip**

> No Yes

Tumo Su

Non-

Katie A. O'Connell,^{1,2}Jacob Thomas,³ Fadi Murad,¹ Anthony Rossi,³ Chrysalyne Schmults¹ ¹Brigham & Women's Hospital Department of Dermatology, Harvard Medical School, Boston, Massachusetts ²School of Medicine, Eastern Virginia Medical School, Norfolk, Virginia

³Memorial Sloan Kettering Cancer Center, New York, New York


Results						
Patient Characteristics	Total	Surgical	Non-Surgical	P-Value		
II patients	143	108	35			
ace, n (%) White Nonwhite	128 (89.5) 15 (10.5)	96 (88.9) 12 (11.1)	32 (91.4) 3 (8.6)	0.48		
PV Infection, n (%) No Yes Unknown	14 (9.8) 24 (16.8) 105 (73.4)	10 (9.3) 16 (14.8) 82 (75.9)	4 (11.4) 8 (22.9) 23 (65.7)	0.45		
ocumented History of STI, n (%) No Yes Unknown	23 (16.1) 19 (13.3) 101 (70.6)	15 (13.9) 15 (13.9) 78 (72.2)	8 (22.9) 4 (11.4) 23 (65.7)	0.48		
ircumcision Status, n (%) No Yes Neonatal Adult Unknown Unknown	54 (37.8) 55 (38.4) 36 (65.5) 6 (10.9) 13 (23.6) 34 (23.8)	43 (39.8) 37 (34.3) 26 (70.3) 3 (8.1) 8 (21.6) 28 (25.9)	11 (31.4) 18 (51.4) 10 (55.6) 3 (16.7) 5 (27.8) 6 (17.1)	0.19		
ocumented History of Penile Disease, n (%) No Yes Phimosis Balanitis/posthitis Psoriasis Urethral stricture Lichen Planus	95 (66.4) 48 (33.6) 11 (7.7) 20 (13.7) 8 (5.6) 3 (2.1) 4 (2.8)	76 (70.4) 32 (29.6) 7 (6.5) 11 (10.1) 5 (4.6) 1 (0.9) 3 (2.8)	$19 (54.3) \\16 (45.7) \\4 (11.4) \\9 (24.3) \\3 (8.6) \\2 (5.7) \\1 (2.9)$	0.080		
ocumented History of Genital Warts, n (%) No Yes	118 (80.3) 29 (19.7)	89 (80.9) 21 (19.1)	27 (78.4) 8 (21.6)	0.74		
umor Charactoristics	Total	Surgioal	Non Surgical			
Tumor Characteristics	Total 147	Surgical	Non-Surgical	P-Value		
II Primary Tumors, n (%)		110 (74.8) 56 7 (15 5)	37 (25.2) 65 2 (13 4)			
ge at Diagnosis, years (median, SD)	59.2 (15.2)	56.7 (15.5)	65.2 (13.4)	0.058		
verall Follow-up Time, months (median, IQR)	53.7 (102)	57.8 (119.4)	50.0 (75.2)	0.063		
umor Diameter, cm (mean, SD)	1.2 (0.8)	1.2 (0.9)	1.1 (0.7)	0.75		

Total	Surgical	Non-Surgical	P-Value
147	110 (74.8)	37 (25.2)	
59.2 (15.2)	56.7 (15.5)	65.2 (13.4)	0.058
53.7 (102)	57.8 (119.4)	50.0 (75.2)	0.063
1.2 (0.8)	1.2 (0.9)	1.1 (0.7)	0.75
40 (27.2)	25 (22.7)	15 (40.5)	
15 (10.2)	12 (10.9)	3 (8.1)	
76 (51.7)	61 (55.5)	15 (40.5)	
16 (10.9)	12 (10.9)	4 (10.8)	0.21
123 (83.7)	95 (86.4)	28 (75.7)	
24 (16.3)	15 (13.6)	9 (24.3)	0.13
	147 59.2 (15.2) 53.7 (102) 1.2 (0.8) 40 (27.2) 15 (10.2) 76 (51.7) 16 (10.9)	147 110 (74.8) 59.2 (15.2) 56.7 (15.5) 53.7 (102) 57.8 (119.4) 1.2 (0.8) 1.2 (0.9) 40 (27.2) 25 (22.7) 15 (10.2) 12 (10.9) 76 (51.7) 61 (55.5) 16 (10.9) 12 (10.9) 123 (83.7) 95 (86.4)	$\begin{array}{c cccc} 147 & 110 (74.8) & 37 (25.2) \\ 59.2 (15.2) & 56.7 (15.5) & 65.2 (13.4) \\ 53.7 (102) & 57.8 (119.4) & 50.0 (75.2) \\ 1.2 (0.8) & 1.2 (0.9) & 1.1 (0.7) \\ \hline 40 (27.2) & 25 (22.7) & 15 (40.5) \\ 15 (10.2) & 12 (10.9) & 3 (8.1) \\ 76 (51.7) & 61 (55.5) & 15 (40.5) \\ 16 (10.9) & 12 (10.9) & 4 (10.8) \\ \hline 123 (83.7) & 95 (86.4) & 28 (75.7) \\ \end{array}$

or Treatments	Initial Treatment N (%)	Local Recurrence N (%)	P-Value
rgical* Mohs Micrographic Surgery Circumcision Excision	110 23 (15.7) 21 (14.3) 62 (42.2)	12 (10.9) 2 (9.5)	
Penectomy	4 (2.7)	10 (16.1)	
n-Surgical Topical Therapy	37 25 (17.0)	8 (21.6) 4 (16.0)	
Imiquimod Fluorouracil	9 (36.0) 16 (64.0)		
Laser Ablation ED&C Cryotherapy	9 (6.1) 2 (1.3) 1 (0.7)	4 (44.4)	0.100

- and genital region should be PSCCis
- with PSCCis
- Not all patients will receive a those who obtain a PR, a to a smaller field
- successfully salvaged
- surgeries/treatment
- When evaluating patients with option for first-line treatment

- of possible delay. Sex Transm Infect. 2009;85(7):527-530.
- Dermatology: a Review. Curr Urol Rep. 2017;18(8):62.



Conclusion

Patients with HPV and chronic inflammatory disease of the penis followed closely for development of Topical therapy is a valuable, noninvasive first-line option for those • 5-Fluorouracil and Imiquimod may be considered as off-label therapy in PSCCis complete response (CR), however in subsequent surgery may be limited Although risk of recurrence is 16% for topical treatment compared to 11% for surgical treatment, all patients treated topically were MMS is a useful option for patients who do not obtain a CR with topical therapy, as it spares patients multiple • A small number of tumors will be refractory to treatment and require multiple treatment modalities to achieve a complete response PSCCis, consider the least invasive

References

1. Lucky MA, Rogers B, Parr NJ. Referrals into a dedicated British penile cancer centre and sources 2. Fortier E, Jr., Cerruti A, Clec'h CL, Azzouzi AR, Bigot P. Benefits of Urologic-Dermatologic Consultations for the Diagnosis of Cutaneous Penile Lesions: A Prospective Study. Clin Genitourin Cancer. 2018;16(2):e421-e424. 3. Stamm AW, Kobashi KC, Stefanovic KB. Urologic